Analysts expect that Avenue Therapeutics Inc (NASDAQ:ATXI) will post earnings per share of ($0.32) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Avenue Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.34). Avenue Therapeutics reported earnings of ($0.25) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 28%. The firm is scheduled to issue its next earnings results on Wednesday, November 13th.
According to Zacks, analysts expect that Avenue Therapeutics will report full year earnings of ($1.79) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.75). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.15) to ($0.77). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Avenue Therapeutics.
Avenue Therapeutics (NASDAQ:ATXI) last posted its earnings results on Wednesday, August 14th. The company reported ($0.43) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.05.
In other news, Director Neil Herskowitz bought 5,000 shares of the stock in a transaction dated Tuesday, June 18th. The shares were acquired at an average price of $5.86 per share, with a total value of $29,300.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Joseph Walter Vazzano sold 4,688 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $5.59, for a total transaction of $26,205.92. Following the completion of the sale, the chief financial officer now directly owns 59,038 shares in the company, valued at approximately $330,022.42. The disclosure for this sale can be found here. 5.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Avenue Therapeutics by 135.7% in the 2nd quarter. BlackRock Inc. now owns 39,933 shares of the company’s stock worth $251,000 after purchasing an additional 22,994 shares during the last quarter. National Asset Management Inc. grew its holdings in shares of Avenue Therapeutics by 9.3% in the 2nd quarter. National Asset Management Inc. now owns 64,750 shares of the company’s stock worth $408,000 after purchasing an additional 5,500 shares during the last quarter. Finally, Spark Investment Management LLC bought a new stake in Avenue Therapeutics during the 1st quarter worth about $144,000. 8.23% of the stock is currently owned by institutional investors and hedge funds.
Shares of ATXI traded down $0.09 during trading hours on Tuesday, hitting $6.15. The stock had a trading volume of 3,911 shares, compared to its average volume of 12,820. The company’s fifty day moving average is $6.04 and its two-hundred day moving average is $5.53. Avenue Therapeutics has a 52 week low of $2.08 and a 52 week high of $7.98. The stock has a market capitalization of $103.33 million, a price-to-earnings ratio of -2.93 and a beta of -0.44.
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.